What this pack is
VIMPAT is the brand name in this record; lacosamide tablets / oral solution is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
VIMPATGeneric namelacosamide tablets / oral solution
How this medicine works
The current label states that the precise mechanism by which VIMPAT exerts antiseizure effects remains incompletely explained. In vitro evidence suggests lacosamide may selectively enhance slow inactivation of voltage-gated sodium channels, stabilising hyperexcitable neuronal membranes. This clue cannot select a dose, prove safe co-use with another sodium-channel medicine or create a class conversion table.
Read source: United States ↗Current regulatory record · reviewed 2026-09-04More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- VIMPAT
- Source-scoped market brand names
- VIMPAT · United StatesCurrent regulator record ↗Current brand label; this page displays only oral tablets and oral solution. A regulatory record does not prove live supply or individual suitability.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- lacosamide tablets / oral solution
- Dosage-form class
- VIMPAT lacosamide film-coated oral tablets (50, 100, 150 and 200 mg per tablet) and oral solution (10 mg/mL, 200 mL per bottle). Tablets must be swallowed whole and not cut; the oral solution requires an appropriate medicine measuring device, not a household teaspoon. Injection is not the same displayed product in this oral dossier.
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
5 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed brand label (revised May 2026; SPL v63)
Lacosamide 50 mg per tablet; 60-tablet unit-dose carton (6 cards of 10)
- Product code
- NDC 0131-2477-60
- Form and route
- VIMPAT lacosamide film-coated oral tablet · oral
- Container
- unit-dose carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- lacosamide
- 50 mglabelled amount per tablet; not an individual's tablet count, frequency, course or stopping instruction
- Package
- 60 tablets per carton
- Labelled appearance
- pink · oval film-coated tablet · imprint SP / 50Unscored; the cited label says not to cut it
United States label · Current U.S. DailyMed brand label (revised May 2026; SPL v63)
Lacosamide 100 mg per tablet; 60-tablet unit-dose carton (6 cards of 10)
- Product code
- NDC 0131-2478-60
- Form and route
- VIMPAT lacosamide film-coated oral tablet · oral
- Container
- unit-dose carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- lacosamide
- 100 mglabelled amount per tablet; not an individual's tablet count, frequency, course or stopping instruction
- Package
- 60 tablets per carton
- Labelled appearance
- dark yellow · oval film-coated tablet · imprint SP / 100Unscored; the cited label says not to cut it
United States label · Current U.S. DailyMed brand label (revised May 2026; SPL v63)
Lacosamide 150 mg per tablet; 60-tablet unit-dose carton (6 cards of 10)
- Product code
- NDC 0131-2479-60
- Form and route
- VIMPAT lacosamide film-coated oral tablet · oral
- Container
- unit-dose carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- lacosamide
- 150 mglabelled amount per tablet; not an individual's tablet count, frequency, course or stopping instruction
- Package
- 60 tablets per carton
- Labelled appearance
- salmon · oval film-coated tablet · imprint SP / 150Unscored; the cited label says not to cut it
United States label · Current U.S. DailyMed brand label (revised May 2026; SPL v63)
Lacosamide 200 mg per tablet; 60-tablet unit-dose carton (6 cards of 10)
- Product code
- NDC 0131-2480-60
- Form and route
- VIMPAT lacosamide film-coated oral tablet · oral
- Container
- unit-dose carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- lacosamide
- 200 mglabelled amount per tablet; not an individual's tablet count, frequency, course or stopping instruction
- Package
- 60 tablets per carton
- Labelled appearance
- blue · oval film-coated tablet · imprint SP / 200Unscored; the cited label says not to cut it
United States label · Current U.S. DailyMed brand label (revised May 2026; SPL v63)
Lacosamide 10 mg per mL; 200 mL glass bottle
- Product code
- NDC 0131-5410-72
- Form and route
- VIMPAT lacosamide oral solution · oral
- Container
- glass bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- lacosamide
- 10 mg/mLlabelled concentration per mL; not the number of mL an individual should measure
- Package
- 200 mL per bottle
- Labelled appearance
- colourless to yellow or yellow-brown liquid · strawberry-flavoured oral solution in a glass bottle · imprint NDC 0131-5410-72Not applicable to this dosage form
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
VIMPAT enlarged label: mg per tablet, concentration per mL, falls, cardiac conduction and withdrawal
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
For tablets, 50, 100, 150 and 200 mg are amounts per tablet and 60 Tablets is the carton count. For oral solution, 10 mg/mL is the concentration per mL and 200 mL is the bottle volume. None is an individual amount. The Medication Guide says to swallow tablets whole without cutting and to use a medicine dropper or cup, not a household teaspoon, for the solution.
- Dizziness, double vision, somnolence, coordination and balance problems can increase fall risk. Older adults or people using another sedating or antiseizure medicine should have the real packs, gait changes, fall history and full medicine list reviewed together.
- VIMPAT can affect the PR interval and is associated with AV block, bradycardia, ventricular arrhythmia and syncope. With heart or conduction disease, or beta blockers, calcium-channel blockers, potassium-channel blockers, sodium-channel blockers or other conduction-affecting medicines, the label sets ECG and monitoring boundaries that the site cannot replace.
- Do not abruptly stop or rapidly self-reduce. Sudden antiseizure-medicine withdrawal can increase seizures, and the Medication Guide warns of status epilepticus. The site provides no taper and cannot convert, rotate or combine VIMPAT one-for-one by milligrams with KEPPRA, LAMICTAL, TEGRETOL or another product.
- New or worsening mood, behaviour or self-harm thoughts require prompt professional contact. Serious rash, fever, swollen glands, jaundice, dark urine or multi-organ hypersensitivity clues also require urgent review, not web-only observation.
- The solution is labelled 10 mg/mL and requires a medicine measuring device. Do not use a household teaspoon, pour by bottle volume or treat milligrams as millilitres. An individual's mL amount must come from the exact prescription and professional review.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-04
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. VIMPAT lacosamide brand label, Medication Guide, four oral-tablet and one oral-solution exact package panels (revised May 2026) ↗Current regulatory record · reviewed 2026-09-04
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about VIMPAT (lacosamide tablets / oral solution). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
VIMPAT is the brand in this record and lacosamide tablets / oral solution is the active-ingredient name. Check both with the dosage form (VIMPAT lacosamide film-coated oral tablets (50, 100, 150 and 200 mg per tablet) and oral solution (10 mg/mL, 200 mL per bottle). Tablets must be swallowed whole and not cut; the oral solution requires an appropriate medicine measuring device, not a household teaspoon. Injection is not the same displayed product in this oral dossier.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. VIMPAT lacosamide brand label, Medication Guide, four oral-tablet and one oral-solution exact package panels (revised May 2026) ↗Current regulatory record · reviewed 2026-09-04
- DailyMed (NLM): FDA-approved VIMPAT lacosamide Medication Guide ↗Current regulatory record · reviewed 2026-09-04
HOW IT WORKS · NOT A TREATMENT PLAN
Mechanism reading: a slow sodium-channel inactivation clue cannot generate switching or combination plans
- Carbamazepine, lamotrigine and others may also involve sodium channels, but their molecules, indications, forms, pharmacokinetics and interactions differ. A shared mechanism term does not permit self-substitution or combination.
- The heart also relies on ion-channel conduction, so a neurological sodium-channel mechanism cannot be read apart from ECG, cardiac history and conduction-affecting medicines.
- Mechanism does not decide genetic testing, older-adult suitability or switching from another antiseizure medicine. Those questions require diagnosis, exact packs, prescription, liver/kidney function, cardiac status and professional assessment.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. VIMPAT lacosamide brand label, Medication Guide, four oral-tablet and one oral-solution exact package panels (revised May 2026) ↗Current regulatory record · reviewed 2026-09-04
- DailyMed (NLM): FDA-approved VIMPAT lacosamide Medication Guide ↗Current regulatory record · reviewed 2026-09-04
- FDA: original approval letter for VIMPAT lacosamide tablets NDA 022253 and injection NDA 022254 (28 Oct 2008) ↗reviewed 2026-09-04
- FDA: original multidisciplinary summary review for VIMPAT NDA 022253/022254 (2008) ↗reviewed 2026-09-04
SOURCE-TRACEABLE ARCHIVE
VIMPATlacosamide tablets / oral solution
This page includes an exact current U.S. public-label package panel for VIMPAT, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval of VIMPAT lacosamide tablets
The FDA original approval letter lists 50, 100, 150 and 200 mg oral tablets under NDA 022253.
FDA: original approval letter for VIMPAT lacosamide tablets NDA 022253 and injection NDA 022254 (28 Oct 2008) ↗Current brand-label effective date
DailyMed SPL v63 covers tablets, oral solution and injection with the current Medication Guide and safety reading.
DailyMed (NLM): current U.S. VIMPAT lacosamide brand label, Medication Guide, four oral-tablet and one oral-solution exact package panels (revised May 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Current public brand labelThis page displays four NDA 022253 unit-dose tablet cartons and the NDA 022255 oral solution, all U.S. Schedule V; not evidence of live supply.
Mainland China, EU, Japan and other markets
Local brand, approval, reference, controlled-drug class, pack and supply are not yet established market by marketNo other-market status is inferred from the U.S. VIMPAT name, NDA, NDC, Schedule V class or package appearance.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Do 50, 100, 150 and 200 mg tell me how many tablets to take?
No. These are amounts per tablet; 60 Tablets is the carton count. Individual tablet count and timing come only from the exact prescription and treating professional.
Can the tablet be cut in half?
The current Medication Guide says to swallow the tablet whole and not cut it. Do not use arithmetic to turn a larger strength into a smaller one or change a dose.
Does 10 mg/mL mean taking 10 mL each time?
No. It is the concentration in each 1 mL. The prescribed number of mL must be calculated from the actual prescription and checked with a medicine measuring device, never a household teaspoon.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.